Skip to main content
Livermore
Livermore
ZHEN

Ensign Peak Advisors, Inc

SEC CIK
0001454984
Latest filing
Aug 14, 2026

AKRO holding history

Akero Therapeutics, Inc. in every 13F filed by Ensign Peak Advisors, Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of AKRO by Ensign Peak Advisors, Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−207,692−100.0%Sold outHolders
Q3 2025207,692$9.86M<0.1%+19,283+10.2%AddedHolders
Q2 2025188,409$10.1M<0.1%+33,365+21.5%AddedHolders
Q1 2025155,044$6.28M<0.1%00.0%UnchangedHolders
Q4 2024155,044$4.31M<0.1%00.0%UnchangedHolders
Q3 2024155,044$4.45M<0.1%−82,450−34.7%ReducedHolders
Q2 2024237,494$5.57M<0.1%+4,950+2.1%AddedHolders
Q1 2024232,544$5.87M<0.1%−720−0.3%ReducedHolders
Q4 2023233,264$5.45M<0.1%+650+0.3%AddedHolders
Q3 2023232,614$11.8M<0.1%+55,000+31.0%AddedHolders
Q2 2023177,614$8.29M<0.1%+2,050+1.2%AddedHolders
Q1 2023175,564$6.72M<0.1%+12,300+7.5%AddedHolders
Q4 2022163,264$8.95M<0.1%−6,770−4.0%ReducedHolders
Q3 2022170,034$5.79M<0.1%+98,543+137.8%AddedHolders
Q2 202271,491$676.0K<0.1%+46,206+182.7%AddedHolders
Q1 202225,285$359.0K<0.1%00.0%UnchangedHolders
Q4 202125,285$535.0K<0.1%00.0%UnchangedHolders
Q3 202125,285$565.0K<0.1%00.0%UnchangedHolders
Q2 202125,285$628.0K<0.1%00.0%UnchangedHolders
Q1 202125,285$733.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.